https://www.selleckchem.com/pr....oducts/vps34-inhibit
Our clinical data suggest that SFTPA1 may serve as a biomarker for predicting a favorable response to immunotherapy for patients with LUAD. Collectively, our study extends the expression profile and potential regulatory pathways of SFTPA1 and may provide a potential biomarker for establishing novel preventive and therapeutic strategies for lung adenocarcinoma. Although the middle temporal artery is used for maxillofacial and otological flap surgeries, the anatomical knowledge of the artery is insufficient to corroborate its us
Like
Comment
Share
